252 related articles for article (PubMed ID: 27226183)
1. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.
Adamczyk-Sowa M; Sowa P; Adamczyk J; Niedziela N; Misiolek H; Owczarek M; Zwirska-Korczala K
J Physiol Pharmacol; 2016 Apr; 67(2):235-42. PubMed ID: 27226183
[TBL] [Abstract][Full Text] [Related]
2. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients.
Adamczyk-Sowa M; Pierzchala K; Sowa P; Polaniak R; Kukla M; Hartel M
J Physiol Pharmacol; 2014 Aug; 65(4):543-50. PubMed ID: 25179086
[TBL] [Abstract][Full Text] [Related]
3. Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.
Adamczyk-Sowa M; Sowa P; Mucha S; Zostawa J; Mazur B; Owczarek M; Pierzchała K
Med Sci Monit; 2016 Jul; 22():2484-91. PubMed ID: 27420299
[TBL] [Abstract][Full Text] [Related]
4. Melatonin acts as antioxidant and improves sleep in MS patients.
Adamczyk-Sowa M; Pierzchala K; Sowa P; Mucha S; Sadowska-Bartosz I; Adamczyk J; Hartel M
Neurochem Res; 2014 Aug; 39(8):1585-93. PubMed ID: 24974099
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
[TBL] [Abstract][Full Text] [Related]
6. Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment.
Adamczyk-Sowa M; Galiniak S; Żyracka E; Grzesik M; Naparło K; Sowa P; Bartosz G; Sadowska-Bartosz I
Oxid Med Cell Longev; 2017; 2017():7905148. PubMed ID: 29181127
[TBL] [Abstract][Full Text] [Related]
7. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
8. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis.
Cantó E; Reverter F; Morcillo-Suárez C; Matesanz F; Fernández O; Izquierdo G; Vandenbroeck K; Rodríguez-Antigüedad A; Urcelay E; Arroyo R; Otaegui D; Olascoaga J; Saiz A; Navarro A; Sanchez A; Domínguez C; Caminero A; Horga A; Tintoré M; Montalban X; Comabella M
Mult Scler; 2012 Jul; 18(7):983-90. PubMed ID: 22183936
[TBL] [Abstract][Full Text] [Related]
9. Plasma osteopontin levels in multiple sclerosis.
Comabella M; Pericot I; Goertsches R; Nos C; Castillo M; Blas Navarro J; Río J; Montalban X
J Neuroimmunol; 2005 Jan; 158(1-2):231-9. PubMed ID: 15589058
[TBL] [Abstract][Full Text] [Related]
10. Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment.
Sadowska-Bartosz I; Adamczyk-Sowa M; Gajewska A; Bartosz G
J Neuroimmunol; 2014 Jan; 266(1-2):67-74. PubMed ID: 24290230
[TBL] [Abstract][Full Text] [Related]
11. Effects of certain micronutrients and melatonin on plasma lipid, lipid peroxidation, and homocysteine levels in rats.
Baydas G; Yilmaz O; Celik S; Yasar A; Gursu MF
Arch Med Res; 2002; 33(6):515-9. PubMed ID: 12505094
[TBL] [Abstract][Full Text] [Related]
12. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
13. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine, vitamin B12 and folate levels in Iranian patients with Multiple Sclerosis: a case control study.
Moghaddasi M; Mamarabadi M; Mohebi N; Razjouyan H; Aghaei M
Clin Neurol Neurosurg; 2013 Sep; 115(9):1802-5. PubMed ID: 23756083
[TBL] [Abstract][Full Text] [Related]
15. Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis.
Roostaei T; Sahraian MA; Hajeaghaee S; Gholipour T; Togha M; Siroos B; Mansouri S; Mohammadshirazi Z; Aghazadeh Alasti M; Harirchian MH
Iran J Allergy Asthma Immunol; 2015 Dec; 14(6):589-95. PubMed ID: 26725556
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis.
Comabella M; Romera C; Camiña M; Perkal H; Moro MA; Leza JC; Lizasoain I; Castillo M; Montalban X
J Neurol; 2006 Jun; 253(6):701-6. PubMed ID: 16511637
[TBL] [Abstract][Full Text] [Related]
17. Processes of plasma protein N-homocysteinylation in multiple sclerosis.
Jamroz-Wiśniewska A; Bełtowski J; Bartosik-Psujek H; Wójcicka G; Rejdak K
Int J Neurosci; 2017 Aug; 127(8):709-715. PubMed ID: 27671515
[TBL] [Abstract][Full Text] [Related]
18. Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
Wawrzyniak S; Rzepiński Ł
Neurol Neurochir Pol; 2020; 54(1):54-61. PubMed ID: 31922582
[TBL] [Abstract][Full Text] [Related]
19. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
